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De Novo Variants Disturbing the Transactivation
Capacity of POU3F3 Cause a Characteristic
Neurodevelopmental Disorder
Lot Snijders Blok,1,2,3,* Tjitske Kleefstra,1,3 Hanka Venselaar,4 Saskia Maas,5 Hester Y. Kroes,6
Augusta M.A. Lachmeijer,6 Koen L.I. van Gassen,6 Helen V. Firth,7 Susan Tomkins,8 Simon Bodek,8
The DDD Study,7 Katrin O˜unap,9,10 Monica H. Wojcik,11,12 Christopher Cunniff,13
Katherine Bergstrom,13 Zoe¨ Powis,14 Sha Tang,14 Deepali N. Shinde,14 Catherine Au,15
Alejandro D. Iglesias,15 Kosuke Izumi,16 Jacqueline Leonard,16 Ahmad Abou Tayoun,17,25
Samuel W. Baker,17 Marco Tartaglia,18 Marcello Niceta,18 Maria Lisa Dentici,18 Nobuhiko Okamoto,19
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Han G. Brunner,1,3,24 and Simon E. Fisher2,3,*
POU3F3, also referred to as Brain-1, is a well-known transcription factor involved in the development of the central nervous system, but
it has not previously been associated with a neurodevelopmental disorder. Here, we report the identification of 19 individuals with het-
erozygous POU3F3 disruptions, most of which are de novo variants. All individuals had developmental delays and/or intellectual
disability and impairments in speech and language skills. Thirteen individuals had characteristic low-set, prominent, and/or cupped
ears. Brain abnormalities were observed in seven of eleven MRI reports. POU3F3 is an intronless gene, insensitive to nonsense-mediated
decay, and 13 individuals carried protein-truncating variants. All truncating variants that we tested in cellular models led to aberrant
subcellular localization of the encoded protein. Luciferase assays demonstrated negative effects of these alleles on transcriptional acti-
vation of a reporter with a FOXP2-derived binding motif. In addition to the loss-of-function variants, five individuals had missense
variants that clustered at specific positions within the functional domains, and one small in-frame deletion was identified. Twomissense
variants showed reduced transactivation capacity in our assays, whereas one variant displayed gain-of-function effects, suggesting a
distinct pathophysiological mechanism. In bioluminescence resonance energy transfer (BRET) interaction assays, all the truncated
POU3F3 versions that we tested had significantly impaired dimerization capacities, whereas all missense variants showed unaffected
dimerization with wild-type POU3F3. Taken together, our identification and functional cell-based analyses of pathogenic variants in
POU3F3, coupled with a clinical characterization, implicate disruptions of this gene in a characteristic neurodevelopmental disorder.
POU3F3 (MIM: 602480) encodes a member of class III of
the POU family of transcription factors. These proteins
all carry a characteristic POU domain that binds with
high affinity to a specific octamer (50-ATGCAAAT-30) or
closely related DNA sequences in the enhancers and pro-
moters of various different target genes.1 The importance
of POU3F3 for the developing brain is reflected in its orig-
inal name Brain-1 (Brn1).2 Best known as a marker of up-
per-layer projection neurons in the cortex,3 POU3F3 is
implicated in the regulation of many key processes in the
development of the central nervous system; these pro-
cesses include cortical neuronal migration,4 upper-layer
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specification and production, and neurogenesis.5–7 How-
ever, the phenotypic consequences of pathogenic germline
variants in human POU3F3 are currently unknown.
We identified a de novo missense variant disrupting
POU3F3 in a female with a severe developmental speech
and language disorder, autism spectrum disorder, and
mild intellectual disability. This variant was absent in con-
trol databases and affected a highly conserved amino acid,
and in silico analyses consistently predicted deleterious ef-
fects on the function of the encoded protein. In addition,
we noted a case report describing a de novo chromosome
2q12.1 deletion in a male with intellectual disability; in
the report, POU3F3 haploinsufficiency was discussed as a
possible pathogenic mechanism.8 Chromosome 6q16.1
deletions that span the closely related, co-expressed ortho-
log, POU3F2 (also known as Brn2; MIM: 600494), cause a
neurodevelopmental disorder with obesity.9 Moreover, it
has been shown that FOXP2 (MIM: 605317), disruptions
of which cause a developmental speech disorder (speech
language disorder-1; MIM: 602081), contains an intronic
binding site for POU3F2.10,11
We used matchmaking initiatives such as Gene-
Matcher12 and the Decipher Database13 to identify addi-
tional individuals with rare germline variants in POU3F3.
Here, we delineate the characteristic phenotypic features
and mutational spectrum of a cohort of 19 individuals
with pathogenic variants in POU3F3. Nearly all (17 out of
19) individuals had a de novo variant in the gene, and all
variants were identified via exome sequencing with a trio
approach. One person (individual 18) had inherited the
variant from an affected mother (individual 19); in this
family, exome sequencing had been performed in the pro-
band and the mother only (duo approach).
The phenotypes of all 19 individuals with POU3F3 vari-
ants were systematically assessed and analyzed. A sum-
mary of the most common phenotypic characteristics is
shown in Table 1, and more details per individual can be
found in Table S1. All individuals with a POU3F3 variant
in our cohort (19/19; 100%) had developmental delays
(DD) and/or an intellectual disability (ID). The level of
functioning was broad, ranging from severe ID in two indi-
viduals to borderline intellectual functioning (WPPSI-IQ
77) in one individual. For individuals in which the severity
of ID and/or DD was known, the majority (8/10; 80%) had
a borderline to moderate level of ID and/or DD.
Given that the first proband in our study (individual 3 in
Table S1) had a severe developmental speech and language
disorder, we paid special attention to the speech and lan-
guage capacities across the entire cohort. All individuals
with POU3F3 variants had delayed speech and language
Table 1. Summary of Phenotypes in Individuals with POU3F3 Variants
Non-Truncating Variants Truncating Variants All Variants Combined
Feature Amount Amount Amount Percentage
Development
Developmental delay (DD) and/or intellectual disability (ID) 6/6 13/13 19/19 100%
Borderline or mild ID 2/6 3/13 5/19 26%
Moderate ID 1/6 2/13 3/19 16%
Severe ID 2/6 0/13 2/19 11%
DD or ID, severity unknown 1/6 8/13 9/19 47%
Speech delay or disorder 6/6 13/13 19/19 100%
Autism Spectrum Disorder (ASD) diagnosis 1/6 6/13 7/19 37%
Neurology
Abnormalities reported on brain MRI 3/4 4/7 7/11a 64%
Hypotonia 3/5 7/13 10/18a 56%
Epilepsy 2/6 0/13 2/19 11%
Drooling 2/5 7/9 9/14a 64%
Other features
Cupped and/or low-set ears 3/6 13/13 16/19 84%
Vision problems 2/6 8/13 10/19 53%
Sleeping problems (often waking up at night) 1/5 4/9 5/14a 36%
Cryptorchidism 0/1 3/10 3/11b 27% of males
A more detailed overview of phenotypic features per individual can be found in Table S1.
aFeature not assessed or not known for all 19 individuals in the cohort.
bFeature only applicable to the 11 males in the cohort.
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development, often with a delayed onset of producing first
words. In two children who spoke their first words at an
appropriate age, a halt in development or regression of
speech in the first years of life was reported. Although
both receptive and expressive language problems were re-
ported, in many children expressive speech capacities
were more impaired than language comprehension.
Almost all individuals received or had received speech
therapy, and commonly reported speech-related problems
were oral motor problems, word finding problems, and
social communication issues. In addition to this, drooling
was reported in 9/14 individuals (64%), and open mouth
behavior was seen in four individuals.
Many individuals had autism-like features, and a formal
diagnosis of autism spectrum disorder (ASD) was made in
7/19 individuals (37%). Although 3/19 (16%) individuals
reached their motor milestones in time, most had delays
in both fine and gross motor development. Hypotonia
was reported in 10/18 individuals (56%). The two individ-
uals with severe ID each had a form of epilepsy: Lennox-
Gastaut syndrome with tonic-clonic seizures in one
individual and a severe seizure disorder with myoclonic
seizures, drop attacks, absences, and tonic-clonic seizures
in the other. In both individuals, capillary hemangiomas
were reported; this feature is not present in the rest of
the cohort. Magnetic resonance imaging (MRI) revealed
cerebral atrophy in both individuals; additionally, white
matter cysts were present in one of them. In total, brain
anomalies were reported in 7 of the 11 individuals (64%)
in which a brain MRI was performed. Anomalies observed
in at least two individuals were delayed myelination, cere-
bral atrophy, and corpus callosum abnormalities.
No significant additional congenital abnormalities were
noted in our collected cohort of 19 individuals. Vision
problems, which mainly included (mild) refraction
errors and strabismus, were reported in 10/19 individuals
(53%). Hearing loss was present in one individual, and nar-
row auditory canals were reported in two other individuals.
Although growth parameters were generally normal, small
hands with short and broad digits, especially broad
thumbs, as well as flat feet and high-arched feet were re-
ported in some of the individuals. Five children (5/14;
36%) had sleeping problems at a young age, waking up
several times per night. Three of the eleven males (27%)
had cryptorchidism.
A comparison of facial features revealed a striking over-
lap in dysmorphisms in individuals with POU3F3 variants.
The cupped, prominent, and often low-set ears, present in
16 of the 19 individuals (84%), were most remarkable.
Other common facial features included full lips, an open-
mouth appearance, a broad and bulbous nasal tip, hyperte-
lorism, epicanthal folds, and peri-orbital fullness (Figure 1).
The types of POU3F3 variants in our cohort were
diverse and included nonsense variants, frameshift vari-
ants, missense variants, and an in-frame deletion of five
amino acids. All variants in this study are annotated with
respect to the GenBank: NM_006236.2 transcript. None
of the identified variants were present in the gnomAD
database. The pLI-score of POU3F3 in gnomAD is 0.89,
and no high-confidence truncating variants in this gene
are present in this dataset, indicating that POU3F3 is espe-
cially intolerant for loss-of-function variance. In 13 of the
19 individuals, we found 12 different nonsense or frame-
shift variants, predicted to truncate POU3F3. For most
genes, when such variants arise, the post-transcriptional
surveillance mechanism of nonsense-mediated mRNA
decay (NMD) helps to prevent translation of aberrant
truncated versions of proteins.14 In mammalian cells this
surveillance mechanism is tightly linked to pre-mRNA
splicing.15 Because POU3F3 is an intronless gene, aberrant
transcripts with truncating variants are insensitive to NMD
and so will still be expressed. These truncating variants
were distributed widely across POU3F3 (Figure 2A) and
are thus predicted to yield truncated proteins of a range
of different sizes.
Five individuals in our cohort had a missense variant. All
were located in one of the two known functional domains
of POU3F3: the POU-specific (POU-S) domain and the
POU-homeobox (POU-H) domain (Figure 2A). Even with
this relatively small number of missense variants, a clear
clustering was seen: two unrelated individuals had an iden-
tical de novomissense variant (c.1085G>T, [p.Arg362Leu]),
and another two individuals had missense variants that
affected the same amino acid (c.1219C>G, [p.Arg407Gly]
and c.1220G>T, [p.Arg407Leu]). One individual had a
c.1367A>G, (p.Asn456Ser) substitution. In addition to
the missense variants, one individual had an in-frame
deletion (c.992_1006del, [p.Gln331_Lys335del]), which
removes five amino acids from within the POU-specific
domain of the encoded protein. For all the missense vari-
ants and the in-frame deletion, highly conserved residues
are affected (Figure 2B). All the missense variants of our
cohort are predicted to be pathogenic by both PolyPhen-
2 and SIFT and have high CADD scores (range 26.9–32.0;
Table S1). We also visualized the non-truncating
variants in a tolerance landscape of POU3F3 by using the
MetaDome web server. The tolerance landscape was
computed as a missense over synonymous ratio, on the ba-
sis of single nucleotide variants in gnomAD in the protein-
coding part of POU3F3. All the non-truncating variants
were located in regions of the protein that are extremely
intolerant to missense variation (Figure S1).
The two known functional domains of POU3F3, con-
nected via a flexible linker, are both required for site-spe-
cific DNA binding with high affinity.16 The POU-S
domain forms four alpha-helices; several direct and
sequence-specific hydrogen bonds are made between
residues in the third helix and the DNA.17 In the
POU-H domain, the third helix is also responsible for
sequence-specific DNA-binding. Two of the missense
variants, c.1085G>T, (p.Arg362Leu) and c.1367A>G,
(p.Asn456Ser), affect residues that are located in the
third helix of the POU-S domain and the POU-H
domain, respectively (Figure 2B).
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We used three-dimensional protein modeling to further
investigate the potential functional impact of the identified
non-truncating variants. The PDB file PDB: 2XSD18 (POU-
domain of POU3F1 bound to DNA) provided a template
for modeling the DNA-binding region of POU3F3, which
spans amino acids 316–466 (Figure 2C). Thismodel revealed
that two of the amino acids (Arg362 and Asn456) that are
substituted in our cohort are directly involved in binding
the major groove of target DNA, consistent with the prior
literature on other POU proteins.16,17 In our model,
Arg362 forms hydrogen bonds with a guanine base in the
DNA of the transcription-factor binding site (Figure S2).
Substitution of a leucine residue at this point of the protein
is predicted to abolish DNA-binding. Similarly, Asn456 is
directly involved in DNA-binding by forming hydrogen
bonds with adenine, an interaction that will be disrupted
by a substitution of serine at this position (Figure S2).
The remaining two missense variants that we identified
are located at position 407 on the edge of the homeodo-
main and at the flexible linker in our linear representation
of POU3F3 (Figure 2B). In the three-dimensional model,
Arg407 lies in the flexible linker between both POU do-
mains, but it is unclear what impact a substitution at this
point would have on protein function (Figure 2C). Lastly,
the in-frame deletion in our cohort is located in the
POU-S domain. Although the amino acids that are deleted
do not directly bind to DNA themselves, it is likely that
their loss will alter domain structure and indirectly disturb
DNA-binding capacities.
To assess the potential functional effects of the POU3F3
variants, we performed a variety of complementary cell-
based assays. We expressed a representative set of nine
POU3F3 variants, as well as wild-type (WT) POU3F3, as
fusions to YFP tags in HEK293 cells. The set of POU3F3 var-
iants included all four missense variants, the in-frame dele-
tion, and four of the truncating variants. Immunoblot
analysis showed that all the expressed YFP-fusion proteins
had the expected molecular weights (Figure S3).
Figure 1. Facial Features of Ten Individuals with a Pathogenic POU3F3 Variant
(A) All individuals in this picture have cupped and/or prominent and often low-set ears, except for individual 4. Other overlapping fea-
tures are full lips, an open-mouth appearance, thick ear helices, a broad and bulbous nasal tip, hypertelorism, epicanthal folds, and peri-
orbital fullness.
(B) Magnification of the ear abnormalities in individuals 1, 9, 12, 13, 14, and 16, respectively.
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We assessed the subcellular localization of the mutant
proteins by using direct fluorescence imaging (Figure 3).
Although two missense variants (p.Arg407Leu and
p.Arg407Gly) map within a computationally predicted nu-
clear localization signal (NLS) motif (Figure 2A), none of
the missense variants disturbed subcellular localization in
this assay. All four tested proteins with a missense variant
were located in the nucleus in a similar manner to
WT. However, all the other tested constructs showed ab-
normalities in subcellular localization patterns compared
to WT. For three truncating constructs (c.196_197delinsT,
[p.Asp66Serfs*26], c.668C>A, [p.Ser223*], and c.1197delG,
[p.Ile400Serfs*16]), aberrant cytoplasmic expression was
Figure 2. Characterization of POU3F3
Variants
(A) Linear representation of POU3F3 (Uni-
Prot: P20264) showing the location of
variants from unrelated families in this
cohort. There are twelve truncating vari-
ants (blue), five missense variants (red),
and one in-frame deletion (magenta).
POU-S (orange) is the POU-specific
domain, and POU-H (green) is the POU-
homeodomain. The shown NLS (nuclear
localization signal) prediction is derived
from cNLS Mapper.27 An overview with
mutation details per subject is provided
in Table S1.
(B) Alignment of part of the POU3F3
amino acid sequence (using ClustalW)
with orthologous sequences from the
following species: Mus musculus, Danio
rerio, Drosophila melanogaster, and Caeno-
rhabditis elegans. Helix boundaries are
defined as previously described.16
(C) Three-dimensional modeling of the
functional domains of POU3F3 binding
to a target DNA sequence (yellow). Amino
acids that are affected by the missense
variants are shown in red (wild-type
side chains are depicted), and the location
of the in-frame deletion is shown in
magenta. A more detailed picture for
two missense variants, p.Arg362Leu and
p.Asn456Ser, can be found in Figure S2.
noted, in addition to the normal nu-
clear expression of the protein. For
two of these constructs (p.Ser223*
and p.Ile400Serfs*16) we observed
protein aggregates just around the
nuclear membrane in a subset of
cells, possibly indicating degradation
of mutant protein (Figures 3 and
S4). Aberrant localization patterns
within the nucleus were observed
for the c.1284C>A, (p.Cys428*) and
c.992_1006del, (p.Gln331_Lys335del)
proteins, and the former showed
small nuclear aggregates in aminority
of cells (Figures 3 and S4).
We next investigated whether the variants affect the
transcription factor activity of the encoded protein.
POU3F3 belongs to the POU family of transcription factors
and is known to share important roles in neurodevelop-
ment with its close paralog POU3F2.5,6 In vitro experiments
suggest that POU3F2 is able to activate an intronic binding
site in FOXP2,10,11 a gene that has been implicated in a rare
neurodevelopmental disorder mainly characterized by se-
vere speech problems (MIM: 602081).19 We hypothesized
that POU3F3 might also be able to activate transcription
via this binding site within FOXP2. To test this hypothesis,
we performed luciferase assays in which a YFP-fusion pro-
tein with POU3F3 or POU3F2 was expressed together with
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a Firefly luciferase construct containing the conserved
FOXP2 binding site (Figure S5), as well as a Renilla
luciferase construct, providing a normalization control
(Figure 4A). POU3F3 was able to increase luciferase expres-
sion as strongly as POU3F2; there was a six-fold increase in
expression compared to the negative control (Figure 4B).
This finding indicates that the known intronic binding
site for POU3F2 can also serve as a functional binding
site for POU3F3.
We used the same luciferase assay to compare our
POU3F3 variant constructs with the POU3F3 WT
construct. All four POU3F3 constructs with truncating var-
iants showed a severe impairment in transcriptional
activation function (Figure 4C). The relative luciferase
expression for these variants was similar to that for the
negative control (a YFP-expression vector without
POU3F3), consistent with the complete or partial loss of
the DNA-binding POU domains of POU3F3. Three of the
non-truncating variants (p.Arg362Leu, p.Asn456Ser, and
p.Gln331_Lys335del) showed partial transactivation ca-
pacity that was significantly lower than that of the WT
construct. The p.Arg407Leu variant led to a significant in-
crease in relative luciferase expression compared to theWT
Figure 3. Subcellular Localization
Direct fluorescence imaging of HEK293
cells expressing YFP-POU3F3 fusion pro-
teins carrying different variants found in
our cohort (green). The nuclei are stained
with DAPI (blue). The scale bar ¼ 10mm.
Pictures showing the aberrant subcellular
localization patterns in a larger amount of
cells for the variants p.Gln331_Lys335del,
p.S223*, p.Ile400Serfs*16, and p.Cys428*
can be found in Figure S4.
construct. No significant difference
compared to WT was seen for the
other missense variant at this posi-
tion (p.Arg407Gly). In summary, all
variants except for the p.Arg407Gly
substitution led to significantly
disturbed transactivation capabilities
in our assays.
POU proteins are well known to
have highly conserved dimerization
properties.10 They bind to target
genes as monomers or dimers and
can form either homo-dimers or het-
ero-dimers involving other family
members.20 To investigate whether
the variants in our cohort affected
the dimerization capacities of
POU3F3, we used bioluminescence
resonance energy transfer (BRET), a
sensitive live-cell assay, to test puta-
tive protein-protein interactions.21
In our assays, the bioluminescent
donor construct encodes a Renilla luciferase (RLuc) fusion
protein, and the fluorescent acceptor construct encodes a
protein fused to YFP. If the proteins of interest are in close
proximity, energy transfer can take place from donor to
acceptor. We tested the ability of each mutant protein to
form dimers with WT POU3F3 (Figure 5A) and with itself
(Figure 5B). In these experiments the missense variants
showed generally intact dimerization capacity, although
the interactions for the p.Asn456Ser variant were slightly
decreased. Two variants that are predicted to cause an early
truncation of POU3F3 (p.Asp66Serfs*26 and p.Ser223*)
showed a complete loss of dimerization capacity in
both conditions. The two other truncating constructs
(p.Ile400Serfs*16 and p.Cys428*) showed a less severe
decrease, although the dimerization capacity was still
significantly different from that of the WT construct. The
p.Gln331_Lys335 protein showed impaired dimerization
with WT POU3F3 but normal capacities for forming
homo-dimers.
All in all, the results of our clinical andmolecular charac-
terization show that diverse variants at different locations
within POU3F3 lead to a neurodevelopmental disorder
with overlapping symptoms. When comparing genotypes
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and phenotypes within the cohort, several findings are of
interest. First, two individuals (individuals 1 and 2) have
a distinct and more severe phenotype compared to the
rest of the cohort; this phenotype includes severe ID, epi-
lepsy, and capillary hemangiomas. These individuals are
unrelated but have an identical p.Arg362Leu variant. In
luciferase assays, this variant showed impaired transcrip-
tion-activation capacity, but it was not lower than that
observed for other mutant constructs. Although the reason
for the more severe and distinct phenotype associated with
the p.Arg362Leu variant remains unclear, a dominant-
negative effect is one possibility, given that the mutant
protein showed normal subcellular localization and dimer-
ization capacities in our assays.
Second, several pathogenic POU3F3 variants appear to
be associated with characteristic facial features, especially
the prominent, often cupped, and low-set ears. These ear
abnormalities were reported independently in all individ-
uals with a truncating variant and in the individuals with
the p.Arg362Leu andp.Gln331_Lys335del variant (Figure 1
and Table S1). Prominent ears were also reported in the
previously published individual with a microdeletion
that included POU3F3.8 The cupped or prominent ears
are not present in the three individuals with the missense
variants p.Arg407Leu, p.Arg407Gly, and p.Asn456Ser. The
two missense variants affecting amino acid Arg407 did not
show loss-of-function effects in our luciferase assay; in fact,
p.Arg407Leu showed evidence of a possible gain-of-func-
tion. The p.Asn456Ser variant had a mild loss-of-function
effect on transcriptional activity. These results suggest
that both loss-of-function and gain-of-function mecha-
nisms of different severity might lead to neurodevelop-
mental disorders with differences on a phenotypic level.
Although the missense variants at positions Arg362 and
Asn456 mediate DNA-binding in the major groove, this is
not the case for Arg407. This residue is located in the flexible
linker between the POU-domains. POU3F2 and POU3F3 are
known to be flexible in terms of spacing preference,16mean-
ing that they can bind to short bindingmotifs that are sepa-
rated by 0, 2, or 3 bp, in contrast to other POU proteins that
have more fixed preferences. Findings from a study of
POU3F2 suggest that the highly conserved arginine residue
at a position analogous to POU3F3 residue 407 is one of
the residues that form a critical region in regulating the
spacing preference of the protein.16 Binding activity experi-
ments showed that mutation of this critical region on the
edge of the flexible linker and the homeodomain leads to
less flexibility in spacing preference for the POU protein.16
Figure 4. Luciferase Assays
(A) Expression constructs used in the luciferase assays: a YFP-fused POU3F3 or POU3F2 construct with a CMV promoter; a Firefly luciferase
reporter construct with a minimal promoter and a preceding intronic FOXP2-derived binding site; and a control construct with Renilla
luciferase under control of a TK promoter.
(B) Results of luciferase assays with WT POU3F3 and WT POU3F2 and the reporter construct with the FOXP2-derived binding site.
Values are expressed relative to the control and represent themean5 SD of three independent experiments, each performed in triplicate
(**** ¼ p < 0.0001 and NS ¼ not significant, using one-way ANOVA and a post-hoc Tukey’s test).
(C) Results of luciferase assay withWT POU3F3 and nine constructs with POU3F3 variants. Values are expressed relative to the control and
represent themean5 SD of three independent experiments, each performed in triplicate (***¼ p< 0.001; ****¼ p< 0.0001; and NS¼ not
significant when compared to WT POU3F3 using one-way ANOVA and a post-hoc Dunnett’s test).
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The missense variants p.Arg407Gly and p.Arg407Leu
show different effects in our luciferase assay: although
p.Arg407Gly did not show any difference compared with
theWT POU3F3 construct, the p.Arg407Leu variant showed
again-of-functioneffect. It isunclearwhythese twodifferent
variants affecting the same Arg407 residue show different
effects on transactivation capacity and how this relates to
pathogenic mechanisms. Possibly, the missense variants at
Arg407 alter the spacing properties of the encoded POU3F3
protein, and the alteration might affect transcriptional acti-
vation depending on the characteristics of the binding site.
The architecture of regulatory DNA sites has been shown to
influence the structure and organization of POU dimeriza-
tion, interaction with other proteins, and DNA-binding
properties and can therefore be critical in determining the
functionality of a transcription factor.18,22
POU3F3 is highly similar to POU3F2; it has nearly iden-
tical (98.7%) amino acid sequences for the POU domains
and the flexible linker. The main differences are found
within the N-terminal region, which contains homopoly-
meric repeats that can function as transcriptional activa-
tion domains.1,23 POU3F3 and POU3F2 share some roles
and have partially redundant functions in cortical
development.4,5 Nonetheless, our study and the previ-
Figure 5. Bioluminescence Resonance
Energy Transfer Assays
(A) Bioluminescence resonance energy
transfer (BRET) assays to measure interac-
tions between WT POU3F3 and mutant
POU3F3 constructs. Bars represent the cor-
rected mean BRET ratio 5 SD of three
independent experiments performed in
triplicate (**** ¼ p < 0.0001; * ¼ p <
0.05; and NS ¼ not significant when
compared to WT using one-way ANOVA
and a post-hoc Tukey’s test). The NLS-
donor construct is a Renilla luciferase
construct with a nuclear localization
signal.
(B) BRET assays to measure homodimeriza-
tion capacity of each mutant POU3F3
construct. Bars represent the corrected
mean BRET ratio 5 SD of three indepen-
dent experiments performed in triplicate
(**** ¼ p < 0.0001; *** ¼ p < 0.001; and
NS ¼ not significant when compared to
WT using one-way ANOVA and a post-
hoc Tukey’s test)
ously published study on POU3F2
haploinsufficiency9 underscore the
fact that two functional copies of
both POU3F3 and POU3F2 are
required for normal neurodevelop-
ment. Microdeletions that span
POU3F2 have been shown previously
to cause a neurodevelopmental disor-
der with obesity.9 In contrast to this
POU3F2-related disorder, pathogenic
variants in POU3F3 do not seem to
be associated with obesity, because this feature is only re-
ported in one of the 19 individuals in our cohort. In addi-
tion to the microdeletions encompassing POU3F2, a single
de novo missense variant in POU3F2 has recently been re-
ported, but the specific location of this variant does not
correspond to any variant reported here for POU3F3.24
Our functional data indicate that a known POU3F2 reg-
ulatory site mapping within the FOXP2 locus11 can also be
bound by POU3F3. By using this binding site, we could
develop luciferase-based assays to index the transactiva-
tion capacities of POU3F3 proteins carrying different etio-
logical variants. Nevertheless, it remains undetermined
whether pathogenic POU3F2 and/or POU3F3 variants actu-
ally have a significant impact on FOXP2 expression in the
proper genomic context in vivo. Future studies (for example
by directly testing for FOXP2 misregulation in individuals
with pathogenic POU3F3 variants) might shed light on
whether putative functional links between the different
genes have physiological relevance for the speech
and language impairments observed in the associated neu-
rodevelopmental disorders.25
We emphasize that exome sequencing coverage is vari-
able for POU3F3; the 50 half of the gene has poor coverage
and the 30 part has good coverage.26 So if the characteristic
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facial phenotype as shown in Figure 1 is recognized in an
individual with an overlapping neurodevelopmental
phenotype, it might be prudent to re-assess any existing
next-generation-sequencing data and/or perform targeted
sequencing of POU3F3. The specific variants identified in
this study were all covered by a sufficient number of allele
counts in gnomAD, and none of these alleles were found in
this large dataset.26
In conclusion, we have shown that pathogenic POU3F3
variants cause a neurodevelopmental disorder with a broad
phenotypic spectrum that includes ID and/or DD, speech
and language problems, hypotonia, and autism spectrum
disorder. Most individuals have mild to moderate delays
in neurodevelopment, but a distinct phenotype of severe
ID and epilepsy is also reported in two individuals with an
identical missense variant. Although most variants result
in loss-of-function effects on the transactivation capacities
of POU3F3, other possible pathogenic mechanisms cannot
be excluded. By showing the effects of POU3F3 dysfunction
in humans, our data highlight the essential functions of
POU3F3 for normal brain development.
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